Open Journal Systems

Natural Approaches in Parkinson's Disease: Exploring Curcumin, Glutathione, and CoQ10

Carlie Ann Bertke

Abstract

This paper evaluates three natural compounds, curcumin, glutathione, and coenzyme Q10, and their possible role in Parkinson’s disease treatment. Since current Parkinson’s medications help manage symptoms but do not reverse the disease, it makes sense that patients may be interested in other natural options. After comparing the claims from the Terry Talks Nutrition video with published studies, the evidence for curcumin and glutathione was mixed and not as convincing as it first seemed. CoQ10 looked the most promising, especially for patients with medication wearing-off, but the data is still early. In the end, these supplements may be useful as complementary therapies someday, but right now they should not be used in place of standard treatment. Overall, this paper shows that these supplements are interesting and worth further study, but more clinical research is needed before they can be strongly recommended.

Keywords

Parkinson’s disease; curcumin; glutathione; coenzyme Q10; oxidative stress; natural therapies

References

Teitelbaum, J. (2023, October 5). Natural approaches to empower people with Parkinson’s disease [Video]. YouTube. https://www.youtube.com/watch?v=ZeuVlIGOXv8

Mayo Clinic Staff. (2024, September 27). Parkinson’s disease: Diagnosis & treatment. Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/parkinsons-disease/diagnosis-treatment/drc-20376062

Sharma, C., Suhalka, P., Sukhwal, P., Jaiswal, N., & Bhatnagar, M. (2014). Curcumin attenuates neurotoxicity induced by fluoride: An in vivo evidence. Pharmacognosy Magazine, 10(37), 61. https://doi.org/10.4103/0973-1296.126663

Ghodsi, H., Rahimi, H. R., Aghili, S. M., Saberi, A., & Shoeibi, A. (2022). Evaluation of curcumin as add-on therapy in patients with Parkinson's disease: A pilot randomized, triple-blind, placebo-controlled trial. Clinical Neurology and Neurosurgery, 218, 107300. https://doi.org/10.1016/j.clineuro.2022.107300

Hauser, R. A., Lyons, K. E., McClain, T., Carter, S., & Perlmutter, D. (2009). Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease. Movement Disorders, 24(7), 979-983. https://doi.org/10.1002/mds.22401

Mischley, L. K., Lau, R. C., Shankland, E. G., Wilbur, T. K., & Padowski, J. M. (2017). Phase IIb Study of Intranasal Glutathione in Parkinson's Disease. Journal of Parkinson's disease, 7(2), 289–299. https://doi.org/10.3233/JPD-161040

Muthukumaran, K., Leahy, S., Harrison, K., Sikorska, M., Sandhu, J. K., Cohen, J., Keshan, C., Lopatin, D., Miller, H., Borowy-Borowski, H., Lanthier, P., Weinstock, S., & Pandey, S. (2014). Orally delivered water soluble Coenzyme Q10 (Ubisol-Q10) blocks on-going neurodegeneration in rats exposed to paraquat: potential for therapeutic application in Parkinson's disease. BMC neuroscience, 15, 21. https://doi.org/10.1186/1471-2202-15-21

Yoritaka, A., Kawajiri, S., Yamamoto, Y., Nakahara, T., Ando, M., Hashimoto, K., Nagase, M., Saito, Y., & Hattori, N. (2015). Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for Parkinson's disease. Parkinsonism & Related Disorders, 21(8), 911-916. https://doi.org/10.1016/j.parkreldis.2015.05.022

Full Text: PDF

Article Level Metrics

Previous Years | Current Year